Trial purpose
Cancer treatment
Tumor type
Genitourinary
Age
18+
Clinical summary
Summary
This randomised, open-label trial consists of five sub-studies in patients with advanced urotheial cancer harbouring FGFR genetic aberrations of various clinical stages of disease progression and prior treatments. The trial has five experimental arms, also called substudies. In Substudy 1, participants with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib monotherapy, at dose level one (orally, 300mg once per day). In Substudy 2, participants with solid tumours will receive derazantinib + atezolizumab. Derazantinib will be administered orally at various dose levels, atezolizumab will be administered at 1200mg every three weeks. In Substudy 3, participants with urothelial cancer will be treated with derazantinib and atezolizumab. Derazantinib will be administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every three weeks. In Substudy 4, participants with urothelial cancer progressing after prior FGFR inhibitor treatment will be randomised to receive either derazantinib alone or a combination of derazantinib and atezolizumab. Derazantinib will be administered orally (300mg, once per day), and atezolizumab will be administered as 1200mg every three weeks. In Substudy 5, participants with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib monotherapy at a dose of 200mg twice daily, taken orally.
Conditions
This trial is treating people with urothelial cancer
Eligibility
Inclusion
- Histologically-confirmed transitional cell carcinoma of the urothelium of the upper or lower urinary tract
- Recurrent or progressing stage IV disease, or surgically unresectable, recurrent or progressing disease
- Documented central FGFR genetic aberration (FGFR1, FGFR2, or FGFR3 mutations / short variants and rearrangements / fusions) (Note; Substudy 2 started with patients requiring an FGFR GA, but this requirement was removed from the protocol later on)
- Measurable disease, as defined by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
- Adequate organ functions as indicated by Screening visit local laboratory values
Exclusion
- Receipt of prior cancer treatment within specific interval periods
- Concurrent evidence of any clinically significant corneal or retinal disorder
- History of clinically significant cardiac disorders
- Known CNS metastases
- Concurrent uncontrolled or active infection with human immunodeficiency virus
- Active hepatitis B or chronic hepatitis B without current antiviral therapy
- Active hepatitis C
- Active tuberculosis
- Severe bacterial, fungal, viral and/or parasitic infections on therapeutic oral or IV medication at the time of first dose of study drug administration
Inclusion
- You have had treatment, but your cancer has come back (relapsed or recurrent).
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You are able to swallow medication by mouth.
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Basilea Pharmaceutica
Scientific Title
An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information